TY - JOUR

T1 - Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections

T2 - a systematic review

AU - Bjerager, Jakob

AU - Hajari, Javad

AU - Klefter, Oliver Niels

AU - Subhi, Yousif

AU - Schneider, Miklos

N1 - Publisher Copyright: © 2024, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2024

Y1 - 2024

N2 - Purpose: To review the risk of systemic adverse events and all-cause mortality following same-day bilateral anti-VEGF injections. Methods: Twelve literature databases were searched for studies on same-session bilateral intravitreal anti-VEGF injections. Studies reporting on systemic adverse events and mortality were included. Data extraction was made independently by two authors and discussed afterwards until consensus was reached. Results: Seven studies were included with a total of 13,406 intravitreal anti-VEGF injections (6703 bilateral injections sessions) given to 689 patients. Across all studies, mean age of patients ranged from 55.7 to 82.5 years, and mean follow-up times ranged from 1.3 to 41 months. Six studies reported on systemic adverse events: Two cases of non-fatal cardiac adverse events were reported after 12,964 injections (6482 bilateral injection sessions) in 626 patients. Four studies reported on death: 12 deaths were recorded after 6233 bilateral injection sessions in a total population of 554 subjects. Conclusions: We suggest that the risk of non-fatal systemic adverse events and death after same-session bilateral anti-VEGF injection is reasonably low, but larger studies with follow-ups of several years are needed to quantify the exact risk. Study registration.: Prospectively registered in PROSPERO, registration ID: CRD42023428254, registration date: 20/05/2023. [Figure not available: see fulltext.].

AB - Purpose: To review the risk of systemic adverse events and all-cause mortality following same-day bilateral anti-VEGF injections. Methods: Twelve literature databases were searched for studies on same-session bilateral intravitreal anti-VEGF injections. Studies reporting on systemic adverse events and mortality were included. Data extraction was made independently by two authors and discussed afterwards until consensus was reached. Results: Seven studies were included with a total of 13,406 intravitreal anti-VEGF injections (6703 bilateral injections sessions) given to 689 patients. Across all studies, mean age of patients ranged from 55.7 to 82.5 years, and mean follow-up times ranged from 1.3 to 41 months. Six studies reported on systemic adverse events: Two cases of non-fatal cardiac adverse events were reported after 12,964 injections (6482 bilateral injection sessions) in 626 patients. Four studies reported on death: 12 deaths were recorded after 6233 bilateral injection sessions in a total population of 554 subjects. Conclusions: We suggest that the risk of non-fatal systemic adverse events and death after same-session bilateral anti-VEGF injection is reasonably low, but larger studies with follow-ups of several years are needed to quantify the exact risk. Study registration.: Prospectively registered in PROSPERO, registration ID: CRD42023428254, registration date: 20/05/2023. [Figure not available: see fulltext.].

KW - Adverse event

KW - Anti-VEGF

KW - Bilateral

KW - Death

KW - Injection

KW - Intravitreal

KW - Mortality

KW - Risk

KW - Same-day

KW - Same-session

KW - Systematic review

U2 - 10.1007/s00417-023-06368-8

DO - 10.1007/s00417-023-06368-8

M3 - Review

C2 - 38194112

AN - SCOPUS:85181882978

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

SN - 0721-832X

ER -